• Chemicals
• Discovery / R&D
• Generics
• Market Trends
• Pharma Industry Trends
• Pricing & Reimbursement
• Regulatory
• Sales & Marketing
• Therapeutic

M&A in pharma

Explores the merits of mega-deal in contrast to a more measured portfolio growth strategy

Although Latin America offers substantial business opportunities for companies, it is a volatile region in economic terms. There is considerable risk involved in investing in the region and companies need to be fully aware of past economic crises and their causes before becoming involved.

Latin America continues to be a region of promising opportunities for commercial pharmaceutical organisations. The region represents a growing consumer base for the drug industry as by 2020 the regional population may be as high as 687 million.

The Latin American pharmaceutical market is now worth $45bn and multinational companies consider success in Brazil and Mexico as essential.

Healthcare & Pharmaceuticals in Latin America - A guide to the markets and regulations provides an excellent overview of the healthcare and pharmaceutical market in 19 Latin American countries.

This 40,000 word report, from URCH Publishing, will provide the reader with an excellent review of the healthcare systems, politics, regulatory framework, major companies and key issues affecting the healthcare sector.

Some of the main issues concerning pharmaceutical companies operating in the region include:

Intellectual Property: Laws on intellectual property remain weak or are not enforced in a number of countries, leading legally ambiguous products on the market.

Generics: Regional governments are making serious attempts to encourage the use of generics (in the past the term bioequivalence was interpreted differing across countries) and Indian companies in particular have made headway into the major markets.

R&D: Companies are finding Latin America an attractive centre for R&D. There are currently an estimate 4,000 clinical trials being conducted. High enrolment rates, lower labour costs and improving regulation have estimated the growth in outsourcing.

Political Situation: Unsettling for multinational companies is the political shift to the left in some countries. However, a number of countries are working to introduce universal healthcare coverage which in turn could create excellent long term opportunities.

Key features of the report:

• Overview of healthcare systems in 19 Latin American countries
• Review of the pharmaceutical market and major companies operating in each country
• Brief guide to the relevant regulatory structure with comment on intellectual property issues.
• Evaluation of the role of the generics in the domestic market

This report can help you:

• Review the key political and government structures that influence business in the region
• Understand the distinct characteristics of the Latin American pharmaceutical market
• Consider how increased democracy will affect healthcare systems in relation to inequality and essential medicines
• Gain insight into how generics are being promoted by a number of governments
• Plan market strategy for successful entry and operation in the region

Countries Covered:

Argentina -  Belize – Bolivia – Brazil – Chile – Colombia - Costa Rica - Costa Rica – Ecuador - El Salvador – Guatemala – Honduras - Mexico -  Nicaragua – Panama – Paraguay – Peru – Uruguay – Venezuela

Executive Summary

Chapter 1: Characteristics of Latin America
Characterising Latin America
Investment in Latin America
The changing political situation in Latin America
Politics and healthcare in Latin America
The Organization of American States

Chapter 2: The Latin American healthcare environment
Approach to Latin American healthcare policy
Population trends
Implications of Latin American healthcare reform for the pharmaceutical industry
The Latin American pharmaceutical markets
Latin America and generics
Intellectual property
Essential medicines
Compulsory licensing
Clinical trials

Chapter 3: Argentina - Healthcare & Pharmaceuticals
Healthcare system
The pharmaceutical market
The pharmaceutical industry
Regulatory
Case study: Indian pharmaceutical companies invest in Argentina
Generics
Intellectual property issues
Clinical trials

Chapter 4: Belize
Healthcare system
Pharmaceutical market

Chapter 5: Bolivia
Healthcare system
Pharmaceutical market
Regulations

Chapter 6: Brazil
Healthcare system
The pharmaceutical market
The domestic pharmaceutical industry
Regulatory
Generics
Intellectual property
Clinical trials
Access to medicines

Chapter 7: Chile
Healthcare system
The pharmaceutical market
The pharmaceutical industry
Generics
Regulatory
Clinical trials

Chapter 8: Colombia
Healthcare system
The pharmaceutical market
The pharmaceutical industry
Intellectual property issues
Generics
Regulatory
Clinical trials

Chapter 9: Costa Rica
Healthcare system
Pharmaceutical market
Pricing
Regulations
Intellectual property

Chapter 10: Ecuador
Healthcare system
Pharmaceutical market
Intellectual property

Chapter 11: El Salvador
Healthcare system
Pharmaceutical market
Generics

Chapter 12: Guatemala
Healthcare system
Pharmaceutical market
Generics
Intellectual property issues

Chapter 13: Honduras
Healthcare system
Pharmaceutical market

Chapter 14: Mexico
Healthcare system
The pharmaceutical market
Generics
Pharmaceutical supply
Multinational pharmaceutical company presence
Clinical trials
Intellectual property issues
Illegal drug importation

Chapter 15: Nicaragua
Healthcare system
Pharmaceutical market

Chapter 16: Panama
Healthcare system
Pharmaceutical market

Chapter 17: Paraguay
Healthcare system
Pharmaceutical market
Pricing
Regulatory
Intellectual property

Chapter 18: Peru
Healthcare system
Pharmaceutical market
Pricing
Generics
Regulations
Clinical trials

Chapter 19: Uruguay
Healthcare system
Pharmaceutical market
Regulatory
Pricing

Chapter 20: Venezuela
Healthcare system
Pharmaceutical market
Case study: Pfizer Venezuela
Generics
Intellectual property issues
Counterfeits
About URCH Publishing

List of Figures

Figure 1.1: Gross national income per capita (PPP international $)
Figure 1.2: Healthcare spending as percent of GDP
Figure 1.3: Life expectancy in Latin America (by country)
Figure 2.1: Latin America - population growth
Figure 2.2: Latin American pharmaceutical market split (2011)
Figure 2.3: Leading pharmaceutical markets in Latin America (2011)
Figure 2.4: Emerging pharmaceutical markets in Latin America (2011)
Figure 2.5: Regional split of Phase III clinical trials (2011)
Figure 3.1: Density of the Health Workforce in Argentina
Figure 6.1: Phase III trials by Country (2011)
Figure 6.2: Phase II trials by Country (2011)
Figure 7.1: Pharmaceutical Market in Chile
Figure 8.1: Growth of Colombian Pharmaceutical Market
Figure 9.1: Costa Rica: Pharmaceutical imports by country
Figure 9.2: Costa Rica: Pharmaceutical exports by country
Figure 12.1: Innovator versus Generic Price Class Comparison in Guatemala
Figure 14.1: Employment in the Mexican Pharmaceutical Industry
Figure 14.2: Share of Mexican Pharmaceutical Market
Figure 18.1: Leading causes of mortality in Peru
Figure 18.2: Mortality rate for communicable diseases in Peru
Figure 19.1: Uruguayan pharmaceutical sector exports
Figure 19.2: Uruguayan pharmaceutical sector imports

List of Tables

Table 1.1: Member countries of the OAS
Table 2.1: Ranbaxy in Latin America
Table 6.1: ANVISA regulations
Table 14.1: Pharmaceutical product types in Mexico